The oncofetal protein IMP3: A novel biomarker for endometrial serous carcinoma

American Journal of Surgical Pathology

Volumn 32, Issue 2, 2008, Pages 304-315

  Zheng, Wenxin ^a,b   Yi, Xiaofang ^b   Fadare, Oluwole ^c,d   Liang, Sharon X ^e   Martel, Maritza ^f   Schwartz, Peter E ^f   Jiang, Zhong ^g  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b FUDAN UNIVERSITY   (China)

^c WILFORD HALL MEDICAL CENTER   (United States)

^d University of Texas Health Science Center at San Antonio   (United States)

^e STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Diagnostic markers; Endometrial cancer; Endometrial glandular dysplasia; Endometrial serous carcinoma; IMP3

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3;

ARTICLE; CANCER CLASSIFICATION; CONTROLLED STUDY; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; TUMOR VOLUME;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; CARCINOMA IN SITU; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; CYTOPLASM; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOENZYME TECHNIQUES; NEOPLASM PROTEINS; PRECANCEROUS CONDITIONS; RNA-BINDING PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 38649132604     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181483ff8     Document Type: Article

References (41)

1. Announcements FIGO stages - 1988 revision. Gynecol Oncol. 1989;35:125-127.
2. Ambros RA, Sherman ME, Zahn CM, et al. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Human Pathol. 1995;26:1260-1267.
3. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10-17.
4. Christopherson WM, Alberhasky RC, Connelly PJ. Carcinoma of the endometrium: I. A clinicopathologic study of clear-cell carcinoma and secretory carcinoma. Cancer. 1982;49:1511-1523.
5. Fadare O, Liang SX, Ulukus EC, et al. Precursors of endometrial clear cell carcinoma. Am J Surg Pathol. 2006;30:1519-1530.
6. Fanning J, Evans MC, Peters AJ, et al. Endometrial adenocarcinoma histologic subtypes: clinical and pathologic profile. Gynecol Oncol. 1989;32:288-291.
7. Gurpide E. Endometrial cancer: biochemical and clinical correlates (review). J Natl Cancer Inst. 1991;83:405-416.
8. Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol. 2006;24:4783-4791.
9. Hendrickson M, Ross J, Eifel P, et al. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol. 1982;6:93-108.
10. Jiang Z, Chu PG, Woda BA, et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol. 2006;7:556-564.
11. Kohler MF, Berchuck A, Davidoff AM, et al. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res. 1992;52:1622-1627.
12. Kurman RJ, Zaino RJ, Norris HJ. Endometrial carcinoma. In: Kurman RJ, ed. Blaustein's Pathology of the Female Genital Tract. 4th ed. New York: Springer-Verlag; 1994:439-486.
13. Lauchlan SC. Tubal (serous) carcinoma of the endometrium. Arch Pathol Lab Med. 1981;105:615-618.
14. Lauchlan SC. The secondary mullerian system revisited. Int J Gynecol Pathol. 1994;13:73-79.
15. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch. 2004;444:213-223.
16. Lax SF. Molecular genetic changes in epithelial, stromal and mixed neoplasms of the endometrium. Pathology. 2007;39:46-54.
17. Liang SX, Cheng L, Chambers SK, et al. Endometrial glandular dysplasia, a newly defined precursor lesion of uterine papillary serous carcinoma: part II, molecular features. Intl J Surg Pathol. 2004;12:319-331.
18. Liao B, Hu Y, Herrick DJ, et al. The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem. 2005;280:18517-18524.
19. Mueller-Pillasch F, Lacher U, Wallrapp C, et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene. 1997;14:2729-2733.
20. Mueller-Pillasch F, Pohl B, Wilda M, et al. Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev. 1999;88:95-99.
21. Mutter GL. Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group Study. Gynecol Oncol. 2000;76:287-290.
22. Mutter GL. Histopathology of genetically defined endometrial precancers. Int J Gynecol Pathol. 2000;19:301-309.
23. Mutter GL. Diagnosis of premalignant endometrial disease. J Clin Pathol. 2002;55:326-331.
24. Mutter GL, Baak JP, Crum CP, et al. Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry. J Pathol. 2000;190:462-469.
25. Nielsen J, Christiansen J, Lykke-Andersen J, et al. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol. 1999;19:1262-1270.
26. Reid-Nicholson M, Iyengar P, Hummer AJ, et al. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol. 2006;19:1091-1100.
27. Saito M, Okamoto A, Kohno T, et al. Allelic imbalance and mutations of the PTEN gene in ovarian cancer. Int J Cancer. 2000;85:160-165.
28. Sasano H, Comerford J, Wilkinson DS, et al. Serous papillary adenocarcinoma of the endometrium. Analysis of proto-oncogene amplification, flow cytometry, estrogen and progesterone receptors, and immunohistochemistry. Cancer. 1990;65:1545-1551.
29. Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol. 2000;13:295-308.
30. Tashiro H, Isacson C, Levine R, et al. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol. 1997;150:177-185.
31. Vikesaa J, Hansen TV, Jonson L, et al. RNA-binding IMPs promote cell adhesion and invadopodia formation. Embo J. 2006;25:1456-1468.
32. Walker AN, Mills SE. Serous papillary carcinoma of the endometrium. A clinicopathologic study of 11 cases. Diagn Gynecol Obstet. 1982;4:261-267.
33. Wang T, Fan L, Watanabe Y, et al. L523S, an RNA-binding protein as a potential therapeutic target for lung cancer. Br J Cancer. 2003;88:887-894.
34. Wheeler DT, Bell KA, Kurman RJ, et al. Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. Am J Surg Pathol. 2000;24:797-806.
35. Yaniv K, Yisraeli JK. The involvement of a conserved family of RNA binding proteins in embryonic development and carcinogenesis [Review] [29 refs]. Gene. 2002;287:49-54.
36. Yaniv K, Fainsod A, Kalcheim C, et al. The RNA-binding protein Vg1 RBP is required for cell migration during early neural development. Development. 2003;130:5649-5661.
37. Yantiss RK, Woda BA, Fanger GR, et al. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol. 2005;29:188-195.
38. Zheng W, Schwartz PE. Serous EIC as an early form of UPSC. Recent progress of its pathogenesis and current opinions of clinical management. Gynecol Oncol. 2005;95:579-582.
39. Zheng W, Khurana R, Farahmand S, et al. p53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma: precursor of uterine papillary serous carcinoma. Am J Surg Pathol. 1998;22:1463-1473.
40. Zheng W, Liang SX, Yu H, et al. Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: Morphologic features. Int J Surg Pathol. 2004;12:207-223.
41. Zheng W, Liang SX, Yi X, et al. Occurrence of endometrial glandular dysplasia precedes uterine papillary serous carcinoma. Int J Gynecol Pathol. 2007;26:38-52.